ProCE Banner Activity

FAQs: The Expanding Role of Antibody–Drug Conjugates in Breast Cancer

Clinical Thought

In this commentary, expert faculty address questions about the emerging data on the potential expanding role of antibody–drug conjugates in the management of breast cancer.

Released: July 21, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO

Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Center
Los Angeles, California

Aditya Bardia, MD, MPH: consultant/advisor: Daiichi Sankyo/AstraZeneca, Foundation Medicine, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Phillips, Radius Health, Sanofi; researcher (paid to institution): Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics/Gilead, Lilly, Merck, Novartis, Pfizer, Radius Health, Sanofi.

Shanu Modi, MD

Professor of Medicine
Section Head, HER2 Breast Program
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Shanu Modi, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Genetech, Gilead, Seattle Genetics; researcher: AstraZeneca, Daiichi Sankyo, Genentech, Seattle Genetics.